{"companyId":285427,"requestedLanguage":"en","resolvedLanguage":"en","availableLanguages":["en","ja"],"companyName":"Veraxa Biotech AG","headOfficeLocation":"Im Neuenheimer Feld 584 Heidelberg, 69120 Germany","presidentName":"Christoph Antz","companySummary":null,"stockCode":"VRXA","currency":"USD","capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["veraxa.com"],"businessContents":["Biopharmaceutical drug development","Cancer immunotherapy and antibody technology"],"relations":[],"dataSources":[{"detailNumber":1,"url":"https://veraxa.com/","scoreAbout":300,"scoreBusiness":200,"scoreGroup":0,"scoreCustomer":0}]}